


CK LIFE SCIENCES

Innovative Therapeutic Vaccines for Cancers of Unmet Need

🌐 Company Introduction

CK Life Sciences Int'l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With an ambition of improving Health & Wellness, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com

🔬 Cancer Vaccine R&D Pipeline



CK Life Sciences' R&D efforts are focused on developing therapeutic cancer vaccines. Our cancer vaccine pipeline includes a melanoma vaccine candidate in Phase 3 clinical trial stage, and Early-Stage, Multi-Indication, cancer vaccine candidates targeting a broad spectrum of tumor antigens, immune checkpoint proteins, and other key components within the tumor-immune microenvironment.

Our promising early-stage pipeline includes vaccine candidates targeting PRAE/PD-L1, TROP2, Claudin 6 and other antigens,. Patents have been filed for our promising inventions.

Executive Team

Chairman
VICTOR LI

President
HL KAM

Deputy Chairman
ALAN YU

Exec Dir/CEO
LANCE YUEN

Exec Dir/CSO
MELVIN TOH

CK LIFE SCIENCES

Innovative Therapeutic Vaccines for Cancers of Unmet Need



Market Opportunity

CK Life Sciences' early-stage cancer vaccine candidates target antigens that are widely expressed in diverse cancer types. PRAME is overexpressed in ~ 90% of Melanoma and ~ 40% of Non-Small Cell Lung Cancer (NSCLC). TROP2 is overexpressed in ~ 80% of Triple-Negative Breast Cancer and ~ 75% of NSCLC. Claudin 6 is overexpressed in ~ 25% of Gastric Cancer and ~ 70% of Ovarian Cancer.

Our early-stage cancer vaccines have multi-indication potential, representing a multi-billion-dollar addressable market. Despite advances like immune checkpoint inhibitors, many cancers remain unmet medical needs. Given their favorable benefit-risk profile, therapeutic cancer vaccines are well-suited for combination with checkpoint inhibitors and other approved cancer therapies.



Financial Status

CK Life Sciences' revenue-generating businesses in Nutraceuticals and Agriculture-related sectors provide steady revenue that enables our R&D sustainability. We are actively pursuing strategies to maximize the value of our pipeline, particularly our promising early-stage cancer vaccines.

CK Life Sciences is well-positioned to realize value for our R&D efforts. We invite investors, bankers, R&D collaborators, and other potential partners to explore opportunities that maximize the value and returns of our R&D efforts, including spin-offs, joint ventures, mergers & acquisitions.









CK Life Sciences Int'l. (Holdings) Inc.
長江生命科技集團有限公司

Innovative Therapeutic Vaccines for Cancers of Unmet Need



CK Life Sciences estimates that funding of approximately US\$50M would be required over the next 3 years to complete GMP manufacturing and IND-enabling studies for 3 cancer vaccine candidates and commence Phase I/II clinical trials for one of these candidates.

	2025		2026				2027				2028	
	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q
CKLS202 PRAME/PD-L1 Vaccine												
<i>Preclinical & Regulatory</i>												
<i>CMC/Manufacturing</i>												
<i>Clinical</i>												
CKLS118 TROP2 Vaccine												
<i>Preclinical & Regulatory</i>												
<i>CMC/Manufacturing</i>												
CKLS121 CLDN-6 Vaccine												
<i>Preclinical & Regulatory</i>												
<i>CMC/Manufacturing</i>			